Provided herein are novel chimeric polypeptides that bind an antigenic peptide (e.g., a viral antigen or a tumor-associated antigen) and activate the endogenous phagocytic signaling pathway. Also provided are compositions and methods useful for producing such chimeric polypeptides, nucleic acids encoding same, phagocytic cells that have been modified to express such chimeric polypeptides, as well as methods for the treatment of various disorders, such as viral infections or cancers.

The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

The present disclosure provides compositions and methods for making and using engineered killer phagocytic cells for immunotherapy in cancer or infection by expressing a chimeric antigen receptor having an enhanced phagocytic activity, the chimeric receptor is encoded by a recombinant nucleic acid.

Described herein is a delivery system that targets leukocytes and in some embodiments monocytes to deliver nucleic acid encoding a chimeric antigen receptor. Additionally, described herein is a method of using a delivery system to transduce leukocytes and in some embodiments monocytes to deliver nucleic acid encoding a chimeric antigen receptor. The delivery system may also function to activate the target cell by providing a ligand to the chimeric antigen receptor. Furthermore, described herein is a delivery system that also include a nucleic acid inhibitor that decreases the expression of a protein that forms a part of the pathway that degrades the chimeric receptor. In embodiments, the binding of a ligand to the extracellular domain of the chimeric receptor activates the intracellular portion of the chimeric receptor. Activation of the intracellular portion of the chimeric receptor may polarize the macrophage into an M1 or M2 macrophage.

Described herein are chimeric receptors. Chimeric receptors comprise a cytoplasmic domain; a transmembrane domain; and an extracellular domain. In embodiments, the cytoplasmic domain comprises a cytoplasmic portion of a receptor that when activated polarizes a macrophage. In further embodiments, a wild-type protein comprising the cytoplasmic portion does not comprise the extracellular domain of the chimeric receptor. In embodiments, the binding of a ligand to the extracellular domain of the chimeric receptor activates the intracellular portion of the chimeric receptor. Activation of the intracellular portion of the chimeric receptor may polarize the macrophage into an M1 or M2 macrophage.

The application relates to the healing of wounds. Provided herein are methods directed to treatment of hard-to-heal or chronic wounds by sequential administration of M1 and M2 macrophages to the wound site

A method of isolating monocyte populations of cells and inducing apoptosis in these populations without production of pro-inflammatory mediators is disclosed. The method comprises isolating the monocytes and, subjecting them to substrate-adherence and serum deprivation conditions. Apoptotic monocytes as prepared are useful for treating inflammation-associated diseases.

In one aspect, the invention provides a composition comprising at least one monocyte comprising an agent that increases monocyte homing to a site of injury, and an effective amount of a drug. In another aspect, the invention provides a method of using the composition to deliver a drug to a site of injury.

The present invention relates to a novel antibody and a use thereof, and more specifically, to: an antibody-drug conjugate or a bispecific antibody comprising the antibody produced by substituting an existing antibody sequence or an antigen-binding fragment thereof, wherein the antibody does not have any glycation-related substances generated in a production process; a pharmaceutical composition comprising the antibody-drug conjugate or bispecific antibody for preventing or treating cancer; a nucleic acid encoding the antibody or an antigen-binding fragment thereof; a vector and a host cell comprising the nucleic acid; and a method for preparing an antibody or an antigen-binding fragment thereof.

The present invention relates to a novel antibody and a use thereof, and more specifically, to: an antibody-drug conjugate or a bispecific antibody comprising the antibody produced by substituting an existing antibody sequence or an antigen-binding fragment thereof, wherein the antibody does not have any glycation-related substances generated in a production process; a pharmaceutical composition comprising the antibody-drug conjugate or bispecific antibody for preventing or treating cancer; a nucleic acid encoding the antibody or an antigen-binding fragment thereof; a vector and a host cell comprising the nucleic acid; and a method for preparing an antibody or an antigen-binding fragment thereof.